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ABSTRACT
The current hepatitis B vaccines needs to be stored 
and transported under refrigerated conditions  
(2 – 8 °C). This dependence on a cold-chain is highly 
challenging in areas where hepatitis B virus  
infections are endemic. To decrease the cold-chain 
dependency, powder formulations of the hepatitis 
B surface antigen (HBsAg) without aluminum were 
prepared by spray-freeze drying in the presence  
of either inulin or a combination of dextran and  
trehalose. The stability of HBsAg in the amorphous 
powder formulations was strongly improved during 
storage both at room temperature and at an  
elevated temperature (60 °C), compared to a liquid 
plain and an aluminum hydroxide adjuvanted 
HBsAg formulation. Immunogenicity studies in mice 
showed that reconstituted powder formulations 
induced higher IgG immune responses after  
intramuscular administration than those induced 
after administration of unprocessed plain antigen. 
Although the immune response was not as high  
as after administration of aluminum adjuvanted 
HBsAg, the immune response to the reconstituted 
vaccines shifted towards a more balanced Th1/Th2 
response compared to the aluminum containing 
HBsAg formulation. 
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INTRODUCTION
Each year, approximately 600,000 persons die due to consequences of acute or chronic hep-
atitis B virus (HBV) infection. It is estimated that 350 million people worldwide carry the 
HBV [1], which makes it a serious threat to global health [2]. Prevalence of chronic HBV 
infection varies markedly throughout the world. High prevalence rates (10 – 20 %) are 
observed within Asia and sub-Saharan Africa, where HBV infection is considered to be 
endemic. In areas like western Europe and North America, less than 1 % of the population 
carries HBV [2],[3].
Vaccination against HBV is known to be a cost effective intervention for HBV infection 
[4],[5]. The currently available HBV vaccine formulations are liquid suspensions containing 
virus-like particles (VLPs) of recombinant hepatitis B surface antigen (HBsAg) adsorbed 
onto aluminum phosphate or aluminum hydroxide. The exact mechanism of how alumi-
num acts as an adjuvant has not been fully elucidated, but seems to be related to inflammo-
some activation and the production of uric acid upon injection induced by aluminum [6-8].
A disadvantage of these formulations is that the vaccine is unstable when frozen 
(below -1 °C) and at elevated temperatures. After freezing and thawing, the aluminum salts 
tend to aggregate [9], which may lead to irritation at the site of injection due to the increased 
size of the aluminum particles. Furthermore, in vivo studies in mice showed that freezing 
reduces the immunogenicity of aluminum adsorbed HBsAg [10]. According to the manu-
facturer of Engerix-B, the stability of the formulation is guaranteed for 3 years only when it 
is stored at a temperature between 2 – 8 °C [11]. Although clinical studies showed that the 
immunogenicity to Engerix-B is not changed after 7 days of storage at 37 °C [12], in vitro 
studies showed a decrease in antigenicity of aluminum adjuvanted HBsAg after 3 to 4 weeks 
of storage at 37 °C [13],[14] or after one to two months at 20 – 25 °C [15]. 
Due to their instability, a “cold chain” is required for current HBsAg vaccines. A “cold 
chain” means that from manufacturing until administration, the formulation has to be 
kept at refrigerator conditions (2 – 8 °C) [16]. Transport and storage at refrigerator condi-
tions is challenging and expensive, especially in high prevalence areas like Southeast Asia 
and sub-Saharan Africa.
By drying biopharmaceuticals, like vaccines, their storage stability can be improved 
[17]. In the dry state the molecular mobility of the protein-based antigen is strongly reduced 
by which the vaccine is less prone to degradation. However, during the drying process pro-
teins may be subjected to harsh conditions that can severely damage them. It is widely 
known that sugars can be used as stabilizing excipients to prevent degradation not only 
during drying but also during storage [18]. To act as a stabilizer, it is essential that during 
drying the sugar becomes glassy and remains in that state during subsequent storage, since 
sugar crystallization would damage the antigen. It is generally believed that three mecha-
nisms are involved in the stabilization of proteins by sugars, these are water replacement 
[19], particle isolation [20], and vitrification [21]. The water replacement theory states that 
during drying the hydrogen bonds between the protein and water molecules are gradually 
replaced by hydrogen bonds between the protein and the hydroxyl groups of the sugar, 
by which the structural integrity of the protein is conserved. According to the particle iso-
lation theory, the sugar molecules form a physical barrier between the individual protein 
molecules by which the protein molecules cannot interact with each other. It is proposed 
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that particle isolation prevents degradation pathways like aggregation. Finally, according 
to the vitrification theory, the glassy sugar matrix strongly reduces the molecular mobility 
of the protein. Since many degradation pathways require molecular mobility, the rate 
at which these degradation pathways occur is strongly reduced. In order to remain in the 
glassy state during processing and storage the sugar should preferably have a high glass 
transition temperature (Tg) and contain low residual moisture levels, since water acts as 
a plasticizer decreasing the Tg.
Various studies have been performed to improve the stability of HBsAg by drying the 
antigen in the presence of sugars. In a study by Chen et al. [22] and in a study by Hirschberg 
et al. [14] trehalose was used as a stabilizer. The Tg of dry trehalose is around 115 °C [23], 
which seems high enough to remain in the glassy state during storage. However, as described 
before, water uptake from the environment or residual water after the drying process can 
lead to a strongly decreased Tg, which might be even below the storage temperature. In a 
study by Maa et al. [24] a combination of trehalose, mannitol and dextran (ratio 3:3:4) was 
used to stabilize HBsAg. The addition of dextran might improve the overall Tg of the combi-
nation, but on the other hand, the Tg of mannitol is low (13 °C), leading to an overall Tg, 
which is lower than that of trehalose alone.
In our study, it was investigated whether sugars with a high Tg could be used to prepare 
stable powder formulations of the hepatitis B vaccine. Inulin and a combination of dextran 
and trehalose respectively, were used as stabilizers for HBsAg during drying and subse-
quent storage. In various studies, it has been shown that inulin can act as an excellent stabi-
lizer for a variety of proteins [17],[25],[26]. The stabilizing capacities of inulin can be ascribed 
to its favorable physico-chemical properties such as high Tg and resistance to crystallization. 
Polysaccharides like dextran, especially high molecular weight dextrans, exhibit similar favor-
able physico-chemical properties. However, due to their bulky nature, high molecular weight 
dextrans cannot accommodate to the irregular surface structure of proteins causing a less 
tight coating around proteins. In literature, a successful application of a combination of 
a high molecular weight dextran and trehalose to improve the storage stability of a protein 
has been described [27]. We hypothesized that such a mixture will combine the benefits of the 
high Tg of dextran and the ability of the disaccharide to accommodate to the irregular surface 
structure of proteins. For this reason, we also investigated a mixture of a high molecular 
weight dextran and trehalose. Spray-freeze drying was chosen as a drying method to produce 
small size spherical particles, which would be suitable for pulmonary administration in future 
research [25]. Therefore, HBsAg was spray-freeze dried in the absence of aluminum, since alu-






Hepatitis B surface antigen (HBsAg) stock solution (1.8 mg/mL in 8 mM phosphate buffer, 
pH 7.2, purity 98.8 %) was purchased from the Serum Institute of India Ltd. (Pune, India). 
Inulin (4 kDa) was a generous gift from Sensus (Roosendaal, The Netherlands). Dextran (70 
kDa), hydrogen peroxide and sodium acetate were obtained from Fluka BioChemika (Buchs, 
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Switserland). Trehalose was obtained from Cargill (Amsterdam, The Netherlands). 
Alhydrogel 2 % (wet gel suspension of aluminum hydroxide) was obtained from Brenntag 
Biosector (Frederikssund, Denmark). Bovine serum albumin (BSA) and 3,3’, 5,5’ 
-tetramethybenzidine (TMB) were obtained from Sigma-Aldrich (Zwijndrecht, The Nether-
lands). Tween 80 was obtained from BUFA (IJsselstein, The Netherlands). Sulfuric acid was 
obtained from Merck (Darmstadt, Germany). The phosphate buffered saline (PBS) used in 
this study consisted of 155 mM sodium chloride, 1.54 mM potassium dihydrogen phos-
phate, 2.7 mM disodium hydrogen phosphate at a pH of 7.2.
Formulations
Powder formulations of the different sugars with and without HBsAg were obtained by 
spray-freeze drying. Aqueous solutions of 2.25 % (w/v) sugar (either inulin or a mixture of 
dextran and trehalose at a weight ratio of 1:1) with and without HBsAg in Milli-Q water at a 
concentration of 90 µg/mL were sprayed at 5 mL/min into a vessel of liquid nitrogen using 
a nozzle of the Büchi 190 Mini Spray Dryer (Büchi, Flawil, Switzerland). The nozzle was 
placed approximately 5 cm above the surface of the liquid nitrogen. The solution was atom-
ized with nitrogen gas at an airflow of 600 Ln/hr. After spraying, the vessel with liquid nitro-
gen was transferred to a Christ model Epsilon 2-4 freeze dryer (Salm & Kipp, Breukelen, The 
Netherlands). After evaporation of the liquid nitrogen, the product was dried for 24 hours at 
a pressure of 0.220 mBar and a condenser temperature of -85 °C, while the shelf tempera-
ture was gradually increased from -35 °C to -10 °C. Next, the pressure was decreased to 0.050 
mBar, while the shelf temperature was gradually increased to 20 °C during 4 hours. At these 
conditions, drying was continued for another 20 hours. After drying, powders were either 
stored for stability testing (see section stability testing) or placed in a vacuum desiccator 
over dried silica gel at room temperature (20 °C±2 °C) until further use.
As a negative control, a HBsAg solution of 90 µg/mL (without any excipients) was 
freeze dried at the same settings as the spray-freeze-dried formulations. HBsAg was freeze 
dried instead of spray-freeze dried because spray-freeze drying HBsAg without excipients 
would imply that the solid content in the feed solution would be extremely low (90 µg/mL 
instead of 22.5 mg/mL for the sugar containing powder formulations), which makes it prac-
tically impossible to collect sufficient amounts of the formed powder properly. Sample col-
lection is not an issue when freeze drying, since the sample remains in the vial during the 
freeze drying process. Spray-freeze drying is a more harsh condition than freeze drying as 
the vaccine is not only subjected to freezing and dehydration stresses but also to shear 
stresses. Therefore, compared to freeze drying, spray-freeze drying can be considered as 
a worst case scenario.
Liquid formulations containing aluminum hydroxide were based on the commercial 
GlaxoSmithKline product [11] and was prepared by adding aluminum hydroxide suspen-
sion to an HBsAg stock solution at a weight ratio of 25:1 (Al3+:HBsAg). The solution was 
diluted with PBS to a concentration of 40 µg/mL HBsAg and gently stirred for one hour. The 
degree of adsorption of HBsAg onto the aluminum hydroxide particles was 98.5 % (±0.2 %) 
after one hour, as determined by centrifugation (10 min at 10,000 rpm) of the formulation 
and analysis of the supernatant by ELISA. Sedimentation of VLPs that were not adsorbed to 
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aluminum during centrifugation did not occur as centrifugation of a diluted stock solution 
(40 µg/mL) did not result in a decrease in concentration (data not shown).
A liquid plain formulation, containing only HBsAg and buffer, was prepared by dilut-
ing the stock solution of HBsAg (1.8 mg/mL) with PBS to 40 µg/mL. 
Stability testing
The two powder formulations (one with inulin and one with a mixture of dextran and treha-
lose) and both liquid formulations (HBsAg solution with and without aluminum hydrox-
ide) were stored at various conditions to evaluate their stability. First, the formulations 
were subjected to ten freeze-thaw cycles, which is a worst-case scenario that can be encoun-
tered during shipping of vaccines [29],[30]. One freeze-thaw cycle consisted of storing 1.5-
mL vials, containing the formulation (powder or liquid), in a freezer at -20 °C for 1.5 hours 
and subsequent thawing for 1.5 hours at room temperature. The liquid was frozen within 30 
minutes. This slow freezing rate was chosen to mimic the freezing rate that may occur 
during transport in the presence of ice packs.
Furthermore, all four formulations were stored at 20 °C and at 60 °C for 1, 2, 4, 6, 9 and 
12 weeks. 20 °C was used as the common room temperature. Storage at 60 °C was chosen as 
extreme condition for accelerated stability testing. Furthermore, this temperature can 
occur in tropical countries when exposed to the sun.
Physico-chemical characterization of the powders
To determine the solid state characteristics, both powders were analyzed by X-ray powder dif-
fraction (XRPD) using a D2 PHASER X-ray diffractometer (Bruker, Delft, The Netherlands) 
with a divergence slit of 1 mm and a detector opening of 5°. To prevent direct radiation form 
the X-ray source on the detector, an air-scatter screen (3 mm) was placed above the sample 
holder. Samples were placed on a silicium zero-background sample holder and rotated at 60 
rpm. Scans were performed from 5 to 40 °2θ with a step size of 0.004 °2θ and 1 s measurement 
per step using CuKα radiation, at a wavelength of 1.5406 Å at 30 kV and 10 mA.
The residual moisture content of the spray-freeze-dried powders was determined by 
Karl-Fisher coulometric water titration using an 831 KF Coulometer (Metrohm Applikon, 
Schiedam, The Netherlands). Powders were dissolved in Hydranal®-Coulomat AG (Karl Fisch-
er reagent) prior to analysis.
Differential Scanning Calorimetry (DSC) was used to determine the Tg of the powder 
formulations after spray-freeze drying. The samples were analyzed in an open aluminum 
pan and placed in a Q2000 DSC (TA Instruments, Ghent, Belgium). The samples were 
pre-heated at 80 ºC for 3 minutes to remove the residual water. After cooling to 20ºC, the 
temperature was raised from 20 to 200 °C at 20 °C/min. 
The inflection point of the step transition in the thermograph was taken as the Tg.Scanning 
electron microscope (SEM) images were recorded with a JEOL JSM 6301-F microscope (JEOL, 
Japan). Powder was applied to a double-sided sticky carbon tape on a metal disk and coated with 
80 nm of gold/palladium in a Balzers 120B sputtering device (Balzars Union, Liechtenstein).
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Antigenicity
Antigenicity was measured by ELISA using an antibody directed against the ‘a’ determinant 
epitopes. The ‘a’ determinant is defined as the amino acid residues 120 – 150 [31-33]. For 
investigation of the antigenicity, a Murex HBsAg version 3 ELISA kit (Murex Biotech Limit-
ed, Dartford, United Kingdom) was used according to the specifications of the manufactur-
er. Samples were, if necessary, dispersed and diluted in PBS to 1 ng/mL and pre-incubated 
for 1 hour at 37 °C in microwells coated with a mixture of mouse monoclonal antibodies 
specific for the ‘a’ determinant of HBsAg. Next, affinity purified goat antibodies to HBsAg, 
conjugated to horseradish peroxidase, were added to the wells and the wells were incubat-
ed at 37 °C for 30 minutes. After washing, a substrate solution containing 3,3’, 5,5’-tetrameth-
ylbenzidine (TMB) and hydrogen peroxide were added. The conversion of TMB by peroxidase 
was stopped after 30 minutes with sulfuric acid and measured spectrophotometrically at 
415 nm with a Benchmark Microplate reader (BioRad, Hercules, CA, USA). A calibration 
curve of a reference HBsAg stock solution was used to determine the amount of intact 
HBsAg in the powder formulations. Antigenicity was expressed as percentage (%) of the 
original HBsAg amount in the formulation. Aluminum hydroxide interfered slightly in the 
ELISA, leading to results up to 110 % of the theoretical value immediately after preparation 
of the formulation. Therefore, all ELISA results of this formulation during the stability 
study have been adjusted accordingly.
Intrinsic Tryptophan Fluorescence Spectroscopy
Intrinsic tryptophan fluorescence spectroscopy was used to study conformational changes 
of HBsAg during storage. Tryptophan fluorescence spectra were obtained by using a PTI 
spectrofluorometer (PTI, Birmingham, AL, USA). Samples were diluted in PBS to 10 µg/mL 
HBsAg, and 1.5 mL of this solution was placed in a 10-mm quartz cuvette and gently stirred. 
An excitation wavelength of 295 nm with slits of 2.5 nm was used. Emission scans were per-
formed from 300 to 400 nm, with slits of 2.5 nm, at a speed of 20 nm/s and at 20.0 °C. These 
emission scans were corrected for background caused by PBS and sugar. The emission 
wavelength was plotted against the fluorescence intensity. The maximum fluorescence 
intensity and the wavelength at which the fluorescence intensity was maximal were used to 
determine changes in the formulations during storage.
 
Lowry protein determination
Total protein content determination was performed by a modified Lowry analysis [34]. In 
brief, 50 µL of 0.3 % (w/v) sodium deoxycholate was added to 500 µL of protein sample and 
incubated for 10 minutes. Next, 50 µL of a 72 % (w/v) trichloroacetic acid was added and 
incubated on ice for 30 minutes to precipitate the protein. The solution was centrifuged and 
the remaining pellet was resuspended in 1 mL of Lowry reagent. Finally, 100 µL Folin solu-
tion was added and incubated for 30 minutes. The absorbance at 750 nm was compared to 
a calibration curve.
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Dynamic Light Scattering (DLS)
The size of the HBsAg VLPs in the liquid plain formulation during storage was measured by 
Dynamic Light Scattering. A 1-cm plastic cuvette containing 1.5 mL of a 10 µg/mL HBsAg 
solution was placed in a Zetasizer Nano Zs (Malvern, Worcestershire, United Kingdom). The 
scattering of a 633 nm laser beam was detected at a 173° angle. Malvern DTS v.5.10 software 
was used to calculate the mean volume diameter of the HBsAg VLPs by an average of 10 scans.
 
Immunization
Animal experiments were conducted according to the guidelines provided by the Dutch 
Animal Protection Act and were approved by the Committee for Animal Experimentation 
(DEC) of the University if Groningen, The Netherlands. For all experiments, 6- to 8-weeks-old 
female BALB/c mice (Harlan, Zeist, The Netherlands) were used. The mice weighed 18 - 20 g 
and were fed ad libitum. Mice, seven in each group, were immunized on day 0 and 14. Prior 
to immunization, all animals were anesthetized with a mixture of isofluran/O2. All formula-
tions (see Table 1) were injected intramuscularly at a volume of 2 x 25 µL, containing 2 µg 
of HBsAg, divided over the hind legs. Spray-freeze-dried samples containing HBsAg and 
sugar(s) were reconstituted in PBS, and injected within 30 minutes after reconstitution. 
Spray-freeze-dried sugar(s) without HBsAg were reconstituted in a solution of HBsAg 
in PBS and injected immediately after reconstitution. The non-spray-freeze-dried formula-
tions were prepared by dissolving the sugar(s) in PBS after which HBsAg was added.
Sample collection
On days 0 and 14, blood samples were taken from the mice by orbital punction under isoflu-
rane/O2 anesthesia. The animals were sacrificed on day 28. Mice were bled under anesthesia 
by draining the abdominal aorta. Serum samples were obtained by centrifugation at 1200 x 
g for 15 minutes and stored at -20 °C until further analysis.
HBsAg antibody ELISA
Specific IgG, IgG1 and IgG2a antibodies against HBsAg in sera were determined by ELISA 
as described by Hirschberg et al. [14]. In brief, 96-well plates (Greiner Microlon®600 F-bot-
tom) were coated with 0.2 µg HBsAg, diluted in PBS, per well. The plates were incubated 
overnight at room temperature. The plates were washed with 0.05 % (w/v) Tween 80 in Mil-
li-Q water. Series of three-fold dilutions of sera were added to the wells. Dilutions were pre-
pared in PBS containing 0.5 % (w/v) BSA and 0.05 % (w/v) Tween 80. After 2 hours 
of incubation at 37 °C, the plates were washed and goat-anti-mouse immunoglobulin con-
jugated to horseradish peroxidase (IgG/IgG1/IgG2a-HRP, Southern Biotech, Birmingham, 
AL, USA) diluted 5000 times in PBS containing 0.5 % (w/v) BSA and 0.05 % (w/v) Tween 80 
was added. The conjugate was incubated for 1 hour at 37 °C. The plates were washed and 
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100 µL of substrate solution containing 0.01 % (w/v) TMB, 10 % 1.1 M sodium-acetate buf-
fer (pH 5.5) and 0.02 % (v/v) hydrogen peroxide (30 %) was added to each well. The conver-
sion of TMB by peroxidase was stopped after 10 minutes with 2 M sulfuric acid and the 
absorbance was measured at 415 nm with a Benchmark Microplate reader. Titers are given 
as the reciprocal of the calculated sample dilution corresponding to an A415=0.2 after back-
ground correction. The lowest dilution was 10 times. Therefore, the limit of quantification 
is 10 Log 10 = 1. In this way, a non-responder is defined as a mouse having a titer below 1 on 
a 10Log-scale. 
Table 1 Formulations used for immunization. SFD: spray-freeze dried
Formulation Components HBsAg Sugar
Plain HBsAg HBsAg in PBS Not SFD -
HBsAg alum HBsAg and aluminum hydroxide in PBS Not SFD -
SFD HBsAg-inu SFD HBsAg with inulin and reconstituted SFD SFD
HBsAg+SFD inu SFD inulin, reconstituted and mixed with HBsAg Not SFD SFD
HBsAg+inu Inulin dissolved and mixed with HBsAg Not SFD Not SFD
SFD HBsAg-dex/tre SFD HBsAg with dextran/trehalose and reconstituted SFD SFD
HBsAg+SFD dex/tre SFD dextran/trehalose, reconstituted and mixed with HBsAg Not SFD SFD
HBsAg+dex/tre Dextran/trehalose dissolved and mixed with HBsAg Not SFD Not SFD
Statistical analysis
Comparisons between formulations and groups were made using a two-tailed Student’s 
t-test. Probability values (P) < 0.05 were considered significant.
RESULTS
 
Physico-chemical characterization of the powders
 
Figure 1 shows the XRPD patterns of both powder formulations and the patterns of (par-
tially) crystalline inulin, dextran 70 kDa and trehalose. Due to periodic arrangement of the 
molecules, crystalline materials will give distinct diffraction peaks at certain positions as 
shown in the diffractograms of the pure sugars. In amorphous material, the molecules are 
randomly distributed. Therefore, the X-rays will be scattered in all directions, resulting in 
the absence of distinct diffraction peaks. The absence of high intensity peaks in the XRPD 
patterns of the powder formulations indicates that the sugar(s) in both powder formula-
tions were amorphous after spray-freeze drying and remained as such during 3 months 
of storage at 60 ºC.
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Table 2 shows the residual moisture content in and the Tg of both powder formulations. 
Th e residual moisture content in both formulations was 2.5 – 3.0 % as measured by 
Karl-Fisher coulometric water titration. Immediately aft er spray-freeze-drying and aft er 
three months of storage at 60 ºC, the Tg of both powder formulations aft er evaporation of 
the residual water was 165 – 170 ºC. Th ese Tg values are in theory high enough for the 
sugar(s) to remain amorphous during storage at 60 °C. Although the residual moisture acts 
as a plasticizer, resulting in a strongly decreased Tg, the visual appearance of the powder did 
not change during storage. Th e powders remained porous and did not collapse upon stor-
age as confi rmed by scanning electron microscopy (Figure 2). Also XRPD results showed 
that both powder formulations remained amorphous during 3 months of storage at 60 °C. 
In conclusion, even though there was some residual moisture aft er spray-freeze-drying, the 
water content was low enough for the Tg to remain above the storage temperature of 60 °C.
Figure 1 XRPD patt erns of (partially) crystalline trehalose, dextran and inulin as received and the two amorphous 
powder formulations immediately aft er spray-freeze drying (t=0) and aft er 3 months of storage at 60ºC (t=91).
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Table 2 Tg values of the two spray freeze dried powders measured immediately after spray-freeze  
drying (SFD) and after 3 months of storage at 60 ºC (n=3; ± S.D.). RMC: residual moisture content.
Formulation RMC (%) Tg (°C)
After SFD 3 months at 60 °C
SFD HBsAg-inu 2.59 (±0.12) 166.70 (±2.03) 164.31 (±0.57)





Figure 2 Scanning electron microscopy image of powder formulations before storage A) HBsAg-inulin, B) 
HBsAg-dextran/trehalose and after 3 months of storage at 60 °C C) HBsAg-inulin, D) HBsAg-dextran/treha-
lose. Bar in the bottom of each image represents 1 µm. 
Process stability
In order to evaluate the stability of HBsAg during spray-freeze drying in the presence of 
excipients and during freeze drying in the absence of excipients, ELISA and intrinsic fluo-
rescence were performed on the material, both before and immediately after (spray-) freeze 
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drying. ELISA measurements demonstrated that over 40 % of the original antigenicity was 
lost when HBsAg was freeze dried in the absence of sugars. (see Table 3). In contrast, spray-
freeze drying in the presence of sugar(s) did not signifi cantly aff ect the antigenicity of 
HBsAg. However, tryptophan fl uorescence intensity of the freeze dried material without 
excipients and the spray-freeze-dried material with either inulin or the dextran/trehalose 
combination showed a small but signifi cant change compared to the fl uorescence intensi-
ty before processing. Th is indicates a slight change in the conformational structure of 
HBsAg during both freeze drying andspray-freeze drying. Th e tryptophan fl uorescence was 
maximal at a wavelength of 326 nm for all formulations, before as well as aft er (spray-)
freeze drying.
Table 3 Th e eff ect of spray-freeze-drying (SFD) and freeze drying (FD) on the conformation of the antigen. 
Post-process values are given relative to the value before processing, for ELISA and tryptophan fl uorescence 
measurements. (Mean; n=3±S.D.)
Analysis HBsAg+inu SFD HBsAg+dex/tre SFD HBsAg FD
ELISA 99.2 % (±1.0) (P=0.39) 98.2 % (±0.9) (P=0.25) 56.1 % (±2.1) (P<0.001)
SFD HBsAg-dex/tre 87.5 % (±1.7) (P=0.02) 84.0 % (±0.4) (P=0.0005) 82.5 % (±0.8) (P<0.0005)
Storage stability
To evaluate the storage stability of the two powder formulations and the two liquid formu-
lations, they were subjected to ten freeze-thaw cycles. Th e samples were also stored at 20 ºC 
and 60 °C for three months.
Freeze-thaw stability
Figure 3 shows the antigenicity of HBsAg in the four diff erent formulations aft er ten freeze-
thaw cycles. Th ese results showed that the antigenicity of HBsAg was completely lost aft er 
ten freeze-thaw cycles when it is formulated with aluminum, as measured by ELISA. 
Already aft er one freeze-thaw cycle a 27.0 % (±6.9) loss of the original antigenicity was mea-
sured in the aluminum containing formulation. In the other formulations, the antigenicity 
was unaff ected aft er ten freeze-thawing cycles.
Th e microscopic appearance of the HBsAg aluminum hydroxide formulation before 
and aft er freeze-thawing (Figure 4) showed that the size of the aluminum hydroxide parti-
cles were increased aft er freeze-thawing from approximately 2 – 3 µm to 60 µm in diameter.
Storage at 20 and 60 °C
Antigenicity
During storage at 20 °C for three months, the antigenicity of HBsAg in both powder formu-
lations and in the liquid plain formulation was unaff ected, as shown by ELISA (Figure 5A). 
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Figure 3 Antigenicity of HBsAg aft er ten freeze-thaw cycles compared to the antigenicity before 
freeze-thawing of the two liquid formulations and two powder formulations. (Mean;n=3±S.D.) bdl: below 
detection limit, *** P<0.001 compared to antigenicity before FT.
Figure 4 Microscopic appearance of HBsAg+alum formulation before (left ) and aft er (right) 
ten freeze-thaw cycles. Bar in the top-right corner represents 60 µm.
Th e antigenicity of the liquid HBsAg aluminum hydroxide formulation, however, decreased 
during the fi rst week aft er which it gradually decreased further over time. 
Aft er 3 months of storage at 60 °C, spray-freeze-dried HBsAg in both powder formula-
tions retained approximately 90 % of its initial antigenicity (Figure 5B). In comparison, in 
freeze dried HBsAg without excipients only 14 % of the original antigenicity (before freeze 
drying) was left . Aft er one week of storage at 60 °C, only 60 % antigenicity was retained in 
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the liquid plain HBsAg formulation and only 20 % in the liquid HBsAg-aluminum hydrox-
ide formulation. We therefore conclude that during storage at 60 °C the antigenicity of 
HBsAg was substantially better preserved in the powder formulations than in both liquid-
formulations.
The degree of adsorption of HBsAg to aluminum hydroxide was monitored during two 
weeks of storage at 20 °C and 60 °C. This was measured by centrifugation of the formulation 
(10 minutes at 10,000 rpm) and quantification of HBsAg in the supernatant by ELISA and 
Lowry protein determination. To check whether unbound HBsAg would be spun down 
during centrifugation, a 40 µg/mL solution of only the antigen (no aluminum) was centri-
fuged. The HBsAg concentration before and after centrifugation was the same (data not 
shown) indicating that free unbound HBsAg would not be spun down by centrifugation. 
After centrifugation of the aluminum containing formulation, no significant amounts of 
HBsAg were detected in the supernatants by Lowry analysis (data not shown), indicating a 
high degree of adsorption immediately after production. ELISA, which is a much more sen-
sitive analysis for HBsAg than Lowry, showed that immediately after preparation almost all 
HBsAg was adsorbed onto the aluminum hydroxide particles (degree of adsorption of 98.6 
% (±0.2), Table 4). The amount of adsorbed HBsAg increased significantly to 99.7 % (±0.0) 
and 100.0 % (±0.0) after 4 hours of storage at 20 °C and 60 °C, respectively, (P<0.005 at both 
storage conditions) and did not change upon further storage. 
Table 4 Degree of adsorption of HBsAg on aluminum at different points in time during the first 2 weeks of 
storage at 20 °C and 60 °C as determined by ELISA. In none of the supernatants HBsAg was found by Lowry 
analysis; (n=3; mean ± S.D.)
Time point 20 °C 60 °C
Start (no storage) 98.6 % (±0.2) 98.6 % (±0.2)
4 hours 99.7 % (±0.0) 100.0 % (±0.0)
1 day 99.5 % (±0.2) 99.9 % (±0.2)
7 days 99.3 % (±0.1) 100.0 % (±0.0)
14 days 99.3 % (±0.2) 100.0 % (±0.0)
Wouter thesis2 copy3.indd   80 28-10-2014   14:28:34
81CHAPTER 4  IMPROVED STORAGE STABILITY AND IMMUNOGENICITY
Figure 5 HBsAg antigenicity during 3 months storage at A) 20 °C and B) 60 °C (% as measured by ELISA).  
• SFD HBsAg-inulin, o SFD HBsAg-dex/tre, ▼ plain HBsAg, ∆ HBsAg + alum; (n=3; mean ± S.D.)
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Fluorescence spectroscopy
Due to the opaque appearance of the alum-HBsAg suspension, it was not possible to obtain 
fluorescence spectra and compare fluorescence intensities of this formulation by the spec-
troscopic methods used in this study. Both powders were reconstituted before analysis and, 
similar to the plain liquid formulation, diluted to 10 µg/mL. An excitation wavelength of 
295 nm was used to selectively excite tryptophan residues in HBsAg. Once excited, elec-
trons of tryptophan can fall back to the ground state and emit light. The intensity of the 
emitted light is strongly dependent on the average local environment of all the tryptophan 
residues. A decrease in intensity, a process called quenching, can be caused by several fac-
tors: e.g. by proton transfer from nearby charged amino acids, by electron acceptors, by 
electron transfer by disulfides, amides, or peptide bonds in the protein backbone or by res-
onance energy transfer among tryptophan residues [35]. The effect of quenching is depen-
dent on the distance between tryptophan and the quencher. Therefore, the intensity of the 
emitted light depends on conformation and composition of the protein. When the confor-
mation of the protein changes, the distance between tryptophan residues and different 
quenchers changes, causing a change in intensity. Furthermore, when the average local 
environment of the tryptophan residues changes, energy transfer from excited tryptophan 
residues to the solvent can occur. This energy transfer results in a red-shift of the maximum 
fluorescence intensity. Before storage the wavelength at the maximum fluorescence inten-
sity was 326 – 327 nm and did not change significantly for any of the formulations during 
storage at both storage conditions (data not shown).
Figure 6 shows the tryptophan fluorescence maximum intensities of both reconsti-
tuted powder formulations and the liquid plain formulation, stored at 20 ºC and 60 °C. 
During storage at 20 ºC, the fluorescent intensity of tryptophan in the two powder formula-
tions hardly changed. The liquid plain formulation, however, showed a substantial decrease 
in intensity after 28 days of storage. 
All formulations stored at 60 ºC showed a decrease in maximum fluorescence intensity 
of the tryptophan residues in HBsAg. The decrease in intensity in both powder formulations 
was of the same magnitude, indicating that in both formulations the rate of conformational 
change was similar. The fluorescent intensity of the liquid plain formulation, however, 
decreased much faster than that of both powder formulations. Furthermore, the intensity of 
the liquid plain formulation predominantly decreased in the first week of storage at 60 °C.
The decrease in tryptophan fluorescence of HBsAg in the plain formulation as shown in 
Figure 6, could be caused by a decrease in HBsAg concentration due to adsorption on the wall 
of the glass vial or by aggregation and subsequent sedimentation of the HBsAg. Therefore, 
during the first 28 days of the stability study the HBsAg protein concentration and the size of 
the HBsAg VLPs in the liquid plain formulation was measured as shown in Table 5. The pro-
tein concentration was determined by Lowry and the size of the HBsAg VLPs was measured 
by DLS. Results showed that before storage the size of the HBsAg VLPs is approximately 20 
nm, which is in agreement with other studies [10]. After 28 days of storage at 20 °C and 60 °C 
the size of the HBsAg VLPs significantly increased to 26 and 27 nm, respectively. At the same 
time the polydispersity index was increased significantly from 0.23 before storage to >0.30 for 
both storage conditions. The protein concentration after 28 days was not changed after 14 
days of storage at 60 °C, but the tryptophan fluorescence is already. 
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Figure 6 Maximum intensity of tryptophan emission after 0, 7, 14, 28, 42, 63 and 91 days of storage at A) 20 °C 
and B) 60 °C. • SFD HBsAg-inulin, o SFD HBsAg-dex/tre, ∆ liquid plain HBsAg; (n=3; mean ± SD) lower although 
not significant. 
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Since the size and concentration is decreased by 80 % in the first 7 days, it is concluded that 
the drop in tryptophan fluorescence intensity in the plain formulation as shown in Figure 6 
is not due to a decreased concentration, but is most likely caused by conformational chang-
es of HBsAg.
Table 5 Protein concentration and the mean volume diameters of the HBsAg VLPs in the plain formulation, 
after storage at 20 °C, and 60 °C. The theoretical protein concentration was 40 µg/mL. * P<0.01, ** P<0.005; 
compared to 0 days
Storage time








0 days 20.1 (±1.3) 41.2 (±4.4) 20.1 (±1.3) 41.2 (±4.4)
14 days 22.6 (±3.0) 41.0 (±4.8) 21.7 (±1.3) 43.8 (±2.4)
28 days 25.6 (±0.6)** 39.5 (±3.3) 26.9 (±1.8)* 36.0 (±1.4)
Immunogenicity
In order to evaluate the immunogenicity of the prepared formulations in vivo, the reconsti-
tuted powder formulations, both liquid formulations and proper controls were adminis-
tered to mice. Mice were immunized at day 0 and received a booster dose at day 14. 
Figure 7 shows the serum IgG titers at day 14 and day 28. Administration of the liquid 
plain formulation resulted in the lowest immune response. Serum of one of the seven mice 
in this group did not contain detectable IgG antibodies against HBsAg. The highest levels of 
antibodies were found after administration of the aluminum hydroxide containing HBsAg 
formulation. The average IgG titer after administration of this formulation was almost 100-
fold higher than that after administration of the liquid plain HBsAg formulation. The immu-
nogenicity of the formulations where neither HBsAg nor the sugar was spray-freeze dried 
(HBsAg+inu and HBsAg+dex/tre) was comparable to the liquid plain formulations: at day 14 
also several non-responders were observed and at day 28 the IgG titer were not significantly 
different compared to the IgG titers after administration of the liquid plain formulation. 
Remarkably, mixing unprocessed HBsAg with SFD sugar (either inulin or dextran/trehalose; 
HBsAg+SFD inu and HBsAg+SFD dex/tre) resulted in IgG titers that were significantly higher 
(p<0.05) than the titers found after administration of the liquid plain formulation. Administra-
tion of the formulations where both HBsAg and sugar were spray-freeze dried (SFD HBsAg-inu 
and SFD HBsAg-dex/tre) resulted in even higher IgG titers, although they were not significant-
ly higher than the titers after administration of the formulations in which only the sugar was 
spray-freeze dried (either inulin or dextran/trehalose; HBsAg+SFD inu and HBsAg+SFD dex/
tre). Even though, the titers were higher than those of the plain formulations, they were not as 
high as after administration of the aluminum hydroxide adsorbed HBsAg formulation.
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Figure 7 Mean serum IgG titers at day 14 and day 28. Titers are shown as the mean of 7 animals, unless 
mentioned otherwise (“x/7” indicates the number of responders). Error bars represent the standard error 
of the mean. Th e stars represent diff erences compared to liquid plain HBsAg administration * P<0.05, ** 
P<0.01, *** P<0.001 
Figure 8 shows the IgG subtype profi le at day 28. In all experimental groups, both IgG1 
and IgG2a antibodies were induced. Th e IgG2a titers in all groups were of the same mag-
nitude (P>0.05). Th e IgG1/IgG2a ratio was the largest in the HBsAg + alum group and sig-
nifi cantly higher than in all the other groups (P=0.028-0.037). Th e IgG1/IgG2a ratio of all 
the other groups were not signifi cantly diff erent from each other, indicating a more bal-
anced Th 1/Th 2 response in all of these groups compared to administration of the HBsAg 
+ alum formulation.
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Figure 8 Mean serum IgG1 and IgG2a titers at day 28. Titers are shown as the mean of 7 animals, 
unless mentioned otherwise. Error bars represent the standard error of the mean. 
DISCUSSION
In this study, we showed that the shelf life of the hepatitis B surface antigen can be increased 
by spray-freeze drying the vaccine in the presence of either inulin or a mixture of dextran 
and trehalose. Th e incorporation of the HBsAg in a matrix of amorphous sugar(s) may 
enable storage and transport without a cold-chain. Secondly, this study indicates that 
spray-freeze-dried sugar(s) improves the immune response to HBsAg.
In line with other studies, we found that the current aluminum adjuvanted HBsAg is 
not stable outside the refrigerator [13]. Ten freeze-thaw cycles that mimicked the slow 
freezing rate in the presence of ice packs during transport, led to a loss of antigenicity of 
HBsAg when formulated with aluminum hydroxide. Optical microscopy of the formulation 
before and aft er freeze-thawing revealed that the size of the aluminum hydroxide salts parti-
cles were increased, which confi rms fi ndings by Maa et al. [36]. In that study it was also shown 
that increased aluminum salt aggregation correlates with a decrease in immunogenicity.
Storage of aluminum adjuvanted HBsAg at both 20 °C and 60 °C resulted in a decreased 
antigenicity (50 % and 80 % loss in the fi rst week, respectively). Th e decrease in antigenici-
ty during storage at 60 °C was larger than the decrease found by Hirschberg et al. at the 
same storage temperature (60 % degraded within one week at 60 °C) [14]. Th e decrease was 
not due to an increased adsorption onto aluminum, since the degree of adsorption was 
already close to 100 % immediately aft er preparation of the formulation. However, the 
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decrease in antigenicity was steep, compared to the decrease in antigenicity of the plain 
formulation, which does not contain aluminum. Wittayanukulluk et al. showed that alumi-
num hydroxide can destabilize adsorped antigens due to an alkaline pH microenvironment 
at the surface of aluminum hydroxide [37]. Another explanation of the strongly decreased 
antigenicity might be the increased binding strength between HBsAg and aluminum 
hydroxide during storage, called ageing or maturation [38]. This means that during storage 
the HBsAg becomes more strongly bound to aluminum hydroxide, which is therefore not 
totally desorbed during ELISA analysis.
Freeze-drying of HBsAg showed that the antigenicity was decreased when dried in the 
absence of any excipients. Furthermore, the remaining antigenicity decreased even further 
upon subsequent storage at 60 °C. Both the process stability and the storage stability of 
HBsAg was improved by incorporation of the antigen in an amorphous matrix of either inu-
lin or a combination of dextran and trehalose. Optimal stability will be obtained when the 
sugar matrix is and remains in its glassy state during storage. This requires formulations 
with a high Tg like the Tg (165-170 ºC) of the powder formulations prepared in this study. 
Residual water in the powder may act as a plasticizer, reducing the Tg. However, as shown by 
XRPD, the sugars remained fully amorphous in both formulations during storage at 60 °C 
indicating that the Tg was well above the storage temperature. Powder formulations sub-
jected to strong temperature changes (freeze-thaw cycles) did not result in a decrease in 
antigenicity. During 3 months of storage at 20 °C, neither the antigenicity nor the confor-
mation of HBsAg changed. At 60 °C, both powder formulations showed an improved stabil-
ity compared to the liquid formulations. Some conformational changes occurred based on 
the changes in fluorescence spectroscopy signal, but the antigenicity hardly changed at 
this high temperature. We hypothesize that during storage at 60 °C, conformational chang-
es occurred that had an effect on the hydrophobic parts of HBsAg (tryptophan environ-
ment), but did not affect the hydrophilic parts of the protein where the epitopes are located 
and, therefore, the antigenicity did not change. By these conformational changes it is clear 
that HBsAg is not fully stable under these harsh conditions.
Even though the antigenicity of both the liquid formulations decreased rapidly upon 
storage, this does not necessarily mean the immunogenicity is decreased [14],[22]. Howev-
er, this study shows that the powder formulations were more stable than the liquid formu-
lations in terms of remaining their antigenicity.
Spray-freeze drying HBsAg in the presence of sugars not only increased the storage 
stability of the antigen, but surprisingly also seems to have a potentiating effect on the 
immune response to HBsAg. The IgG titers in sera of mice that received reconstituted spray-
freeze-dried HBsAg formulations were higher than after administration of the liquid plain 
formulation and also the number of responders was higher. The results suggest that the 
improved immune response compared to the liquid plain formulation might be related to 
the processing of the antigen but it is more likely to be caused by spray-freeze drying of the 
sugar(s). This is confirmed by the lower immune response after administration of the for-
mulations where neither the sugar nor the antigen was spray-freeze dried compared to the 
immune response after administration of the formulations where only the sugar was spray-
freeze dried. In a study by Amorij et al. it was found that the immune response after pulmo-
nary administration of spray-freeze-dried influenza vaccine in the presence of inulin was 
better than after pulmonary administration of a liquid plain formulation (antigen in buffer) 
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[25]. The adjuvating effect could be due to the formation of insoluble sugar particles during 
the spray-freeze drying process. From the literature it is known that some crystalline forms 
of inulin can act as an adjuvant [39]. Although XRPD measurements showed that inulin 
was fully amorphous after spray-freeze drying, a minor amount (below detection limits) of 
crystalline inulin may still have been present. The same principle might be true for the for-
mulation containing dextran and trehalose. Stenekens et al. showed that insoluble parti-
cles of dextran can be formed in aqueous supersaturated dextran solutions [40]. At this 
moment the exact mechanism behind the apparent adjuvating effect of spray-freeze-dried 
sugars is unclear. Further research is needed to unravel this phenomenon.
Although the immune response was improved when the sugar was spray-freeze dried, 
the immune response was not as high as after administration of the aluminum adjuvanted 
HBsAg formulation. However, for all formulations where the sugar was spray-freeze dried 
and for the aluminum containing formulation, all mice showed antibodies against HBsAg 
at day 14. The potency assay of the hepatitis B vaccine described in the European Pharma-
copoeia states is solely based on the number of responders after one dose and not on the 
extent of the immune response. In this light both powder formulations and the aluminum 
containing HBsAg formulation are equally potent and they are all more potent than the liq-
uid plain formulation.
A final advantage of the reconstituted powder formulations is that they elicit a more 
balanced Th1/Th2 immune response than the liquid HBsAg formulation containing alumi-
num hydroxide. This could lead to a better protection against HBV, but should ideally be 
supported by clinical studies focusing on protection.
CONCLUSION
Our study shows that incorporation of HBsAg in an amorphous matrix of inulin or a com-
bination of dextran and trehalose by spray-freeze drying, results in a formulation that is 
more stable than the aluminum hydroxide containing formulation, based on the current 
GlaxoSmithKline product. Both powder formulations can be stored for at least 3 months at 
room temperature, without any change in antigenicity or conformation of the HBsAg pro-
tein. Next to this improved stability, administration of the reconstituted powder formula-
tions appears to elicit an improved immune response compared to administration of the 
unprocessed antigen without processed sugars.
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